KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to $502.9 million.

  • Royalty Pharma's Other Non-Current Liabilities rose 891322.58% to $502.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $502.9 million, marking a year-over-year increase of 891322.58%. This contributed to the annual value of $12.1 million for FY2024, which is 124222.22% up from last year.
  • As of Q3 2025, Royalty Pharma's Other Non-Current Liabilities stood at $502.9 million, which was up 891322.58% from $467.1 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Other Non-Current Liabilities peaked at $502.9 million during Q3 2025, and registered a low of $900000.0 during Q4 2023.
  • Over the past 4 years, Royalty Pharma's median Other Non-Current Liabilities value was $11.7 million (recorded in 2023), while the average stood at $80.4 million.
  • Per our database at Business Quant, Royalty Pharma's Other Non-Current Liabilities tumbled by 8054.92% in 2023 and then surged by 891322.58% in 2025.
  • Quarter analysis of 4 years shows Royalty Pharma's Other Non-Current Liabilities stood at $2.5 million in 2022, then tumbled by 64.0% to $900000.0 in 2023, then soared by 1242.22% to $12.1 million in 2024, then skyrocketed by 4063.39% to $502.9 million in 2025.
  • Its last three reported values are $502.9 million in Q3 2025, $467.1 million for Q2 2025, and $17.9 million during Q1 2025.